texas oncology more breakthroughs. more victories
search

Share:

 
 

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Bladder Cancer

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 Pembro + BCG High-risk Bladder View

Description: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Brain Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Breast Cancer

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Cervical Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Colon Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Endometrial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Esophageal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Fallopian Tube Cancer

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

GI Stromal Tumor (GIST)

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Grapevine

Phase: III

Head and Neck Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Leukemia

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Liver Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Lung Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 M7824 vs Pembro NSCLC View

Description: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 M7824 vs Pembro NSCLC View

Description: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Lymphomas

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Melanoma

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Myelofibrosis

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Ovarian Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Pancreatic Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Peritoneal Cancer

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Prostate Cancer

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Rectal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Renal Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Solid Tumors

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Urothelial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Texas Oncology-Arlington North

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Texas Oncology-Arlington South

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Bedford

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 M7824 vs Pembro NSCLC View

Description: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Texas Oncology-Fort Worth Cancer Center

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Pembro + BCG High-risk Bladder View

Description: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Texas Oncology-Grapevine

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Grapevine

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph2 M7824 vs Pembro NSCLC View

Description: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

No Phase

Title: Managed Access Program (MAP) to provide alpelisib for patients with HR+ advanced or metastatic breast cancer resistant or refractory to available treatment options View

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Title: Non-Interv study Palbo HR+/HER2 AdvBC View

Description: POLARIS: Palbociclib in Hormone Receptor Positive AdvancedBreast Cancer: A Prospective Multicenter Non-Interventional Study (A5481082)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1/1b Immunotherapy Combo in NSCLC View

Description: (AB928CSP0004) A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 SY-1365 Solid Tumors View

Description: A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors: SY-1365-101

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Solid tumors, RCC View

Description: (AB928CSP0005) A Phase 1 Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Advanced Malignancies

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Phase I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph 1b/2 SVB-S6-500 + Doxorubicin Ovarian View

Description: A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination with Pegylated Liposomal Doxorubicin or Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer (AVB500-OC-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Phase II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: TALAZ IN GERMLINE BRCA1/2 MUT BC View

Description: (C3441020) A PHASE 2, NON-RANDOMIZED, OPEN LABEL, SINGLE ARM, MULTI-CENTER STUDY OF TALAZOPARIB FOR NEOADJUVANT TREATMENT OF GERMLINE BRCA1/2 MUTATION PATIENTS WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with Umbralisib (TGR-1202) for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Poziotinib EGFR/HER2 NSCLC View

Description: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 M7824 vs Pembro NSCLC View

Description: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 M7824 vs Pembro NSCLC View

Description: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer(MS200647-0037)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Brigatinib ALK+ NSCLC (TAK2002) View

Description: Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in older pts w/1L cHL or PTCL View

Description: A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Abirat+pred +/- abemaciclib mCRPC View

Description: A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 INCMGA00012 mSCAC View

Description: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 Urothelial FGF/FGFR View

Description: A Phase 2, Open-label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Haboring FGF/FGFR Alterations

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 enfortumab (ASG-22CE)Urothelial View

Description: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Phase III

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Pembro + BCG High-risk Bladder View

Description: A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy (A011202)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: CONTESSA:Ph3 Tesetaxel+Cape mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 BLU-285 vs Regorafenib GIST View

Description: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Indication: GI Stromal Tumor (GIST)

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adj canakinumab NSCLC View

Description: A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)(CACZ885T2301)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View

Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo+Rucap Ovarian (ATHENA) View

Description: Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Phase III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV